Role of urotensin II in health and disease

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 298, Issue 5, 2010, Pages

  Ross, Bryan ^a   McKendy, Katherine ^a   Giaid, Adel ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Autocrine paracrine; Experimental animals; Human; Somatostatin; UT receptor

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 14; HUMAN UROTENSIN II; N(G) NITROARGININE; PALOSURAN; PHENYLEPHRINE; RECEPTOR BLOCKING AGENT; RECOMBINANT UROTENSIN II; SB 611812; SB 657510 A; UNCLASSIFIED DRUG; URANTIDE; UROTENSIN II; UROTENSIN RECEPTOR;

ADRENAL TUMOR; ATHEROSCLEROSIS; CALCIUM TRANSPORT; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; DIABETES MELLITUS; DISEASE ACTIVITY; DOSE RESPONSE; DRUG TARGETING; FISH; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY; KIDNEY FAILURE; LUNG; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RECEPTOR BLOCKING; REVIEW; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASODILATATION; VERTEBRATE;

ANIMALS; AUTOCRINE COMMUNICATION; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY DISEASES; METABOLIC SYNDROME X; PARACRINE COMMUNICATION; UROTENSINS; VASOCONSTRICTION;

EID: 77951707590     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00706.2009     Document Type: Review

References (155)

1. Abdelrahman AM, Pang CCY. Involvement of the nitric oxide/L-arginine and sympathetic nervous systems on the vasodepressor action of human urotensin II in anesthetized rats. Life Sci 71: 819-825, 2002.
2. Affolter JT, Newby DE, Wilkinson IB, Winter MJ, Balment RJ, Webb DJ. No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. Br J Clin Pharmacol 54: 617-621, 2002. (Pubitemid 36002589)
3. Alberti KGMM, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 366: 1059-1062, 2005. (Pubitemid 41338752)
4. Albertin G, Casale V, Ziolkowska A, Spinazzi R, Malendowicz LK, Rossi GP, Nussdorfer GG. Urotensin-II and UII-receptor expression and function in the rat adrenal cortex. Int J Mol Med 17: 1111-1115, 2006.
5. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ, Hay DWP, Ohlstein EH, Bergsma DJ, Douglas SA. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401: 282-286, 1999. (Pubitemid 129515542)
6. Balat A, Pakir IH, Gok F, Anarat R, Sahinoz S. Urotensin-II levels in children with minimal change nephrotic syndrome. Pediatr Nephrol 20: 45-45, 2005.
7. Balment RJ, Song W, Ashton N. Urotensin II: ancient hormone with new functions in vertebrate body fluid regulation. Ann NY Acad Sci 1040: 66-73, 2005. (Pubitemid 40979760)
8. Behm DJ, McAtee JJ, Dodson JW, Neeb MJ, Fries HE, Evans CA, Hernandez RR, Hoffman KD, Harrison SM, Lai JM, Wu C, Aiyar N, Ohlstein E, Douglas S. Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues. Br J Pharmacol 155: 374-386, 2008.
9. Bennett RT, Jones RD, Morice AH, Smith CFC, Cowen ME. Vasoconstrictive effects of endothelin-1, endothelin-3, and urotensin II in isolated perfused human lungs and isolated human pulmonary arteries. Thorax 59: 401-407, 2004.
10. Bicak U, Karabiber H, Ozerol HI, Aslan M, Ilhan A, Yakinci C. Possible pathogenic link between migraine and urotensin-II. J Child Neurol 23: 1249-1253, 2008.
11. Böhm F, Pernow J. Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol 135: 25-27, 2002. (Pubitemid 34102094)
12. Boivin S, Guilhaudis L, Milazzo I, Oulyadi H, Davoust D, Fournier A. Characterization of urotensin-II receptor structural domains involved in the recognition of U-II, URP, and urantide. Biochemistry 45: 5993-6002, 2006. (Pubitemid 43727091)
13. Boivin S, Ségalas-Milazzo I, Guilhaudis L, Oulyadi H, Fournier A, Davoust D. Solution structure of urotensin-II receptor extracellular loop III and characterization of its interaction with urotensin-II. Peptides 29: 700-710, 2008.
14. Bottrill F, Douglas S, Hiley C, White R. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 130: 1865-1870, 2000.
15. Boucard A, Sauvé S, Guillemette G, Escher E, Leduc R. Photolabelling the rat urotensin II/GPR14 receptor identifies a ligand-binding site in the fourth transmembrane domain. Biochem J 370: 829-838, 2003. (Pubitemid 36399074)
16. Rakowski E, Hassan GS, Dhanak D, Ohlstein EH, Douglas SA, Giaid A. A role for urotensin II in restenosis following balloon angioplasty: use of selective UI receptor blocker. J Mol Cell Cardiol 39: 785-791, 2005. (Pubitemid 41464415)
17. Bousette N, Patel L, Douglas SA, Ohlstein EH, Giaid A. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 176: 117-123, 2004. (Pubitemid 39078653)
18. Bousette N, Pottinger J, Ramli W, Ohlstein EH, Dhanak D, Douglas SA, Giaid A. Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease. Peptides 27: 2919-2926, 2006. (Pubitemid 44584417)
19. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179: 77-79, 1973.
20. Carmine Z, Mallamaci F. Urotensin II: a cardiovascular and renal update. Curr Opin Nephrol Hypertens 17: 199-204, 2008.
21. Charles CJ, Rademaker MT, Richards AM, Yandle TG. Urotensin II: Evidence for cardiac, hepatic and renal production. Peptides 26: 2211-2214, 2005.
22. Chen YH, Yandle TG, Richards AM, Palmer SC. Urotensin II immunoreactivity in the human circulation: evidence for widespread tissue release. Clin Chem 55: 2040-2048, 2009.
23. Cheriyan J, Burton T, Bradley T, Wallace S, Mäki-Petäjä K, Mackenzie I, McEniery C, Brown J, Wilkinson I. The effects of urotensin II and urantide on forearm blood flow and systemic haemodynamics in humans. Br J Clin Pharmacol 68: 518-523, 2009.
24. Cheung BM, Leung R, Man YB, Wong LY. Plasma concentration of urotensin II is raised in hypertension. J Hypertens 22: 1341-1344, 2004. (Pubitemid 38888080)
25. Clozel M, Binkert C, Birker-Robaczewska M, Boukhadra C, Ding SS, Fischli W, Hess P, Mathys B, Morrison K, Muller C, Muller C, Nayler O, Qiu C, Rey M, Scherz MW, Velker J, Weller T, Xi JF, Ziltener P. Pharmacology of the urotensin-II receptor antagonist Palosuran {ACT-058362; 1-[2-(4-Benzyl-4- hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt}: first demonstration of a pathophysiological role of the urotensin system. J Pharmacol Exp Ther 311: 204-212, 2004. (Pubitemid 39302621)
26. Clozel M, Hess P, Qiu C, Ding SS, Rey M. The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. J Pharmacol Exp Ther 316: 1115-1121, 2006. (Pubitemid 43345285)
27. Conlon J, Arnold-Reed D, Balment RJ. Post-translational processing of prepro-urotensin II. FEBS Lett 266: 37-40, 1990.
28. Coulouarn Y, Lihrmann I, Jegou S, Anouar Y, Tostivint H, Beauvillain JC, Conlon JM, Bern HA, Vaudry H. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA 95: 15803-15808, 1998. (Pubitemid 29018781)
29. Djordjevic T, BelAiba RS, Bonello S, Pfeilschifter J, Hess J, Gorlach A. Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler Thromb Vasc Biol 25: 519-525, 2005. (Pubitemid 40315672)
30. Do-Rego JC, Chatenet D, Orta MH, Naudin B, Le Cudennec C, Leprince J, Scalbert E, Vaudry H, Costentin J. Behavioral effects of urotensin-II centrally administered in mice. Psychopharmacology 183: 103-117, 2005. (Pubitemid 41484187)
31. Douglas S, Naselsky D, Ao Z, Disa J, Herold CL, Lynch F, Aiyar N. Identification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines. Br J Pharmacol 142: 921-932, 2004. (Pubitemid 39037042)
32. Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV, Ohlstein EH, Willette RN. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 131: 1262-1274, 2000.
33. Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 359: 1990-1997, 2002.
34. Dschietzig T, Bartsch C, Pregla R, Zurbrügg H, Armbruster F, Richter C, Laule M, Romeyke E, Neubert C, Voelter W, Baumann G, Stangl K. Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure. Regul Pept 110: 33-38, 2002. (Pubitemid 35435330)
35. Dschietzig T, Richter C, Bartsch C, Böhme C, Heinze D, Ott F, Zartnack F, Baumann G, Stangl K. Flow-induced pressure differentially regulates endothelin-1, urotensin II, adrenomedullin, and relaxin in pulmonary vascular endothelium. Biochem Biophys Res Commun 289: 245-251, 2001. (Pubitemid 33108822)
36. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 365: 1415-1428, 2005.
37. Fang S, Li Z, Wu H, Tang C, Lu Q, Liu H, Yan Q. Clinical study of plasma urotensin II in patients with coronary heart disease. Di Yi Jun Yi Da Xue Xue Bao 24: 563-565, 2004.
38. Flohr S, Kurz M, Kostenis E, Brkovich A, Fournier A, Klabunde T. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structureactivity relationships and nuclear magnetic resonance studies on urotensin II. J Med Chem 45: 1799 - 1805, 2002.
39. Gardiner SM, March JE, Kemp PA, Davenport AP, Bennett T. Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats. Br J Pharmacol 132: 1625-1629, 2001.
40. Gibson A. Complex effects of Gillichthys urotensin II on rat aortic strips. Br J Pharmacol 91: 205-212, 1987. (Pubitemid 17083477)
41. Giuliani L, Lenzini L, Antonello M, Aldighieri E, Belloni AS, Fassina A, Gomez-Sanchez C, Rossi GP. Expression and functional role of urotensin-II and its receptor in the adrenal cortex and medulla: novel insights for the pathophysiology of primary aldosteronism. J Clin Endocrinol Metab 94: 684-690, 2009.
42. Gold S, Thompson J, Williams J, Helm E, Sadler J, Song W, Ng L, Lambert D. Does cigarette smoking increase plasma urotensin II concentrations? Eur J Clin Pharmacol 63: 253-257, 2007. (Pubitemid 46233152)
43. Gruson D, Rousseau MF, Ahn SA, van Linden F, Ketelslegers JM. Circulating urotensin II levels in moderate to severe congestive heart failure: its relations with myocardial function and well established neurohormonal markers. Peptides 27: 1527-1531, 2006. (Pubitemid 44236010)
44. Hassan GS, Douglas SA, Ohlstein EH, Giaid A. Expression of urotensin-II in human coronary atherosclerosis. Peptides 26: 2464-2472, 2005. (Pubitemid 41676718)
45. Heller J, Schepke M, Neef M, Woitas R, Rabe C, Sauerbruch T. Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. J Hepatol 37: 767-772, 2002. (Pubitemid 35404215)
46. Heringlake M, Kox T, Uzun O, Will B, Bahlmann L, Klaus S, Eleftheriadis S, Armbruster FP, Franz N, Kraatz E. The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease. Regul Pept 121: 129-136, 2004. (Pubitemid 38901071)
47. Hillier C, Berry C, Petrie MC, O'Dwyer PJ, Hamilton C, Brown A, McMurray J. Effects of urotensin II in human arteries and veins of varying caliber. Circulation 103: 1378-1381, 2001. (Pubitemid 32220627)
48. Holleran B, Beaulieu M, Proulx C, Leduc R. Photolabelling the urotensin II receptor reveals distinct agonist- and partial-agonist-binding sites. Biochem J 402: 51-61, 2007. (Pubitemid 46254907)
49. Holleran BJ, Domazet I, Beaulieu ME, Yan LP, Guillemette G, Lavigne P, Escher E, Leduc R. Identification of transmembrane domain 6 & 7 residues that contribute to the binding pocket of the urotensin II receptor. Biochem Pharmacol 77: 1374-1382, 2009.
50. Hongfang J, Cong B, Zhao B, Zhang C, Liu X, Zhou W, Shi Y, Tang C, Junbao D. Effects of hydrogen sulfide on hypoxic pulmonary vascular structural remodeling. Life Sci 78: 1299-1309, 2006. (Pubitemid 43199950)
51. Hood SG, Watson AMD, May CN. Cardiac actions of central but not peripheral urotensin II are prevented by β-adrenoceptor blockade. Peptides 26: 1248-1256, 2005.
52. Horie S, Yasuda S, Tsurumaki Y, Someya A, Saito T, Okuma Y, Nomura Y, Hirabayashi T, Murayama T. Contraction of isolated guinea-pig ileum by urotensin II via activation of ganglionic cholinergic neurons and acetylcholine release. Neuropharmacology 45: 1019-1027, 2003. (Pubitemid 37297927)
53. Huitron-Resendiz S, Kristensen MP, Sanchez-Alavez M, Clark SD, Grupke SL, Tyler C, Suzuki C, Nothacker HP, Civelli O, Criado JR, Henriksen SJ, Leonard CS, de Lecea L. Urotensin II modulates rapid eye movement sleep through activation of brainstem cholinergic neurons. J Neurosci 25: 5465-5474, 2005. (Pubitemid 40800638)
54. Ishihata A, Ogaki T, Aita T, Katano Y. Role of prostaglandins in urotensin II-induced vasodilatation in the coronary arteries of aged rats. Eur J Pharmacol 523: 119-126, 2005. (Pubitemid 41562383)
55. Itoh H, Itoh Y, Rivier J, Lederis K. Contraction of major artery segments of rat by fish neuropeptide urotensin II. Am J Physiol Regul Integr Comp Physiol 252: R361-R366, 1987.
56. Itoh H, McMaster D, Lederis K. Functional receptors for fish neuropeptide urotensin II in major rat arteries. Eur J Pharmacol 149: 61-66, 1988.
57. Jarolim P. Serum biomarkers for heart failure. Cardiovasc Pathol 15: 144-149, 2006.
58. Jégou S, Cartier D, Dubessy C, Gonzalez BJ, Chatenet D, Tostivint H, Scalbert E, Leprince J, Vaudry H, Lihrmann I. Localization of the urotensin II receptor in the rat central nervous system. J Comp Neurol 495: 21-36, 2006. (Pubitemid 43238049)
59. Joyal D, Huynh T, Aiyar N, Guida B, Douglas S, Giaid A. Urotensin-II levels in acute coronary syndromes. Int J Cardiol 108: 31-35, 2006. (Pubitemid 43324903)
60. Katano Y, Ishihata A, Aita T, Ogaki T, Horie T. Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries. Eur J Pharmacol 402: 209-211, 2000. (Pubitemid 30625329)
61. Katugampola SD, Kuc RE, Maguire JJ, Davenport AP. G-proteincoupled receptors in human atherosclerosis: comparison of vasoconstrictors (endothelin and thromboxane) with recently de-orphanized (urotensin-II, apelin and ghrelin) receptors. Clin Sci 103, Suppl 48: 171S-175S, 2002.
62. Kawaguchi Y, Ono T, Kudo M, Kushikata T, Hashiba E, Yoshida H, Kudo T, Furukawa K, Douglas SA, Hirota K. The effects of benzodiazepines on urotensin II-stimulated norepinephrine release from rat cerebrocortical slices. Anesth Analg 108: 1177-1181, 2009.
63. Kemp W, Krum H, Colman J, Bailey M, Yandle T, Richards M, Roberts S. Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension. Liver Int 27: 1232-1239, 2007. (Pubitemid 47543152)
64. Kemp W, Roberts S, Krum H. Increased circulating urotensin II in cirrhosis: potential implications in liver disease. Peptides 29: 868-872, 2008. (Pubitemid 351522364)
65. Khan SQ, Bhandari SS, Quinn P, Davies JE, Ng LL. Urotensin II is raised in acute myocardial infarction and low levels predict risk of adverse clinical outcome in humans. Int J Cardiol 117: 323-328, 2007. (Pubitemid 46507623)
66. Kruger S, Graf J, Kunz D, Stickel T, Merx MW, Hanrath P, Janssens U. Urotensin II in patients with chronic heart failure. Eur J Heart Fail 7: 475-478, 2005. (Pubitemid 40732974)
67. Labarrère P, Chatenet D, Leprince J, Marionneau C, Loirand G, Tonon MC, Dubessy C, Scalbert E, Pfeiffer B, Renard P, Calas B, Pacaud P, Vaudry H. Structure-activity relationships of human urotensin II and related analogues on rat aortic ring contraction. J Enzyme Inhib Med Chem 18: 77-88, 2003. (Pubitemid 36622124)
68. Lacza Z, Busija D. Urotensin-II is a nitric oxide-dependent vasodilator in the pial arteries of the newborn pig. Life Sci 78: 2763-2766, 2006.
69. Langham RG, Kelly DJ, Gow RM, Zhang Y, Dowling JK, Thomson NM, Gilbert RE. Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. Am J Kidney Dis 44: 826-831, 2004. (Pubitemid 39445914)
70. Lapp H, Boerrigter G, Costello-Boerrigter LC, Jaekel K, Scheffold T, Krakau I, Schramm M, Guelker H, Stasch JP. Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy. Int J Cardiol 94: 93-97, 2004. (Pubitemid 38314694)
71. Lim M, Honisett S, Sparkes CD, Komesaroff P, Kompa A, Krum H. Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation 109: 1212-1214, 2004. (Pubitemid 38372777)
72. Lin L, Ding WH, Jiang W, Zhang YG, Qi YF, Yuan WJ, Tang CS. Urotensin-II activates L-arginine/nitric oxide pathway in isolated rat aortic adventitia. Peptides 25: 1977-1984, 2004.
73. Lin Y, Tsuchihashi T, Matsumura K, Abe I, Iida M. Central cardiovascular action of urotensin II in conscious rats. J Hypertens 21: 159-165, 2003. (Pubitemid 36143521)
74. Liu Q, Pong SS, Zeng Z, Zhang Q, Howard AD, Williams DL, Davidoff M, Wang R, Austin CP, McDonald TP, Bai C, George SR, Evans JF, Caskey CT. Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem Biophys Res Commun 266: 174-178, 1999. (Pubitemid 30028787)
75. Loirand G, Rolli-Derkinderen M, Pacaud P. Urotensin II and atherosclerosis. Peptides 29: 778-782, 2008.
76. Lu Y, Zou CJ, Huang DW, Tang CS. Cardiovascular effects of urotensin II in different brain areas. Peptides 23: 1631-1635, 2002. (Pubitemid 35246283)
77. Luci DK, Lawson EC, Ghosh S, Kinney WA, Smith CE, Qi J, Wang Y, Minor LK, Maryanoff BE. Generation of novel, potent urotensin-II receptor antagonists by alkylation-cyclization of isoindolinone C3-carbanions. Tetrahedron Lett 50: 4958-4961, 2009.
78. MacLean M, Alexander D, Stirrat A, Gallagher M, Douglas S, Ohlstein E, Morecroft I, Polland K. Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol 130: 201-204, 2000. (Pubitemid 30261027)
79. Maguire J, Kuc R, Davenport AP. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 131: 441-446, 2000.
80. Maguire JJ, Davenport AP. Is urotensin-II the new endothelin? Br J Pharmacol 137: 579-588, 2002.
81. Maguire JJ, Kuc RE, Wiley KE, Kleinz MJ, Davenport AP. Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides 25: 1767-1774, 2004.
82. Malagon MM, Molina M, Gahete MD, Duran-Prado M, Martinez- Fuentes AJ, Alcain FJ, Tonon MC, Leprince J, Vaudry H, Castaño JP, Vazquez-Martinez R. Urotensin II and urotensin II-related peptide activate somatostatin receptor subtypes 2 and 5. Peptides 29: 711-720, 2008.
83. Mallamaci F, Cutrupi S, Pizzini P, Tripepi G, Zoccali C. Urotensin II and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease. Am J Hypertens 19: 505-510, 2006.
84. Mallamaci F, Pizzini P, Tripepi G, Zoccali C. Urotensin II in end-stage renal disease: an inverse correlate of sympathetic function and cardiac natriuretic peptides. J Nephrol 18: 727-732, 2005. (Pubitemid 43085439)
85. Marchese A, Heiber M, Nguyen T, Heng HH, Saldivia VR, Cheng R, Murphy PM, Tsui LC, Shi X, Gregor P, George SR, O'Dowd BF, Docherty JM. Cloning and chromosomal mapping of three novel genes, GPR9, GPR10, and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors. Genomics 29: 335-344, 1995.
86. Marco J, Egido EM, Hernández R, Silvestre RA. Evidence for endogenous urotensin-II as an inhibitor of insulin secretion: study in the perfused rat pancreas. Peptides 29: 852-858, 2008. (Pubitemid 351522366)
87. Matsushita M, Shichiri M, Imai T, Iwashina M, Tanaka H, Takasu N, Hirata Y. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens 19: 2185-2190, 2001. (Pubitemid 33135240)
88. Morimoto R, Satoh F, Murakami O, Totsune K, Arai Y, Suzuki T, Sasano H, Ito S, Takahashi K. Immunolocalization of urotensin II and its receptor in human adrenal tumors and attached non-neoplastic adrenal tissues. Peptides 29: 873-880, 2008. (Pubitemid 351522359)
89. Ng LL, Loke I, O'Brien RJ, Squire IB, Davies JE. Plasma urotensin in human systolic heart failure. Circulation 106: 2877-2880, 2002. (Pubitemid 35424734)
90. Nothacker HP, Wang Z, McNeill AM, Saito Y, Merten S, O'Dowd B, Duckles SP, Civelli O. Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nat Cell Biol 1: 383-385, 1999. (Pubitemid 129493582)
91. Ong KL, Wong LYF, Cheung BMY. The role of urotensin II in the metabolic syndrome. Peptides 29: 859-867, 2008.
92. Ong KL, Wong LYF, Man YB, Leung RYH, Song YQ, Lam KSL, Cheung BMY. Haplotypes in the urotensin II gene and urotensin II receptor gene are associated with insulin resistance and impaired glucose tolerance. Peptides 27: 1659-1667, 2006. (Pubitemid 43884768)
93. Ozer O, Davutoglu V, Ercan S, Akcay M, Sari I, Sucu M, Celik A, Aksoy N, Cicek H, Al B. Plasma urotensin II as a marker for severity of rheumatic valve disease. Tohoku J Exp Med 218: 57-62, 2009.
94. Pakala R. Role of urotensin II in atherosclerotic cardiovascular diseases. Cardiovasc Revasc Med 9: 166-178, 2008. (Pubitemid 351905943)
95. Papadopoulos P, Bousette N, Al-Ramli W, You Z, Behm DJ, Ohlstein EH, Harrison SM, Douglas SA, Giaid A. Targeted overexpression of the human urotensin receptor transgene in smooth muscle cells: effect of UT antagonism in ApoE knockout mice fed with Western diet. Atherosclerosis 204: 395-404, 2009.
96. Patacchini R, Santicioli P, Giuliani S, Grieco P, Novellino E, Rovero P, Maggi C. Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta. Br J Pharmacol 140: 1155-1158, 2003. (Pubitemid 38117417)
97. Pearson D, Shively JE, Clark BR, Geschwind II, Barkley M, Nishioka RS, Bern HA. Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci USA 77: 5021-5024, 1980. (Pubitemid 11236553)
98. Prosser HCG, Leprince J, Vaudry H, Richards AM, Forster ME, Pemberton CJ. Cardiovascular effects of native and non-native urotensin II and urotensin II-related peptide on rat and salmon hearts. Peptides 27: 3261-3268, 2006. (Pubitemid 44738201)
99. Qi J, Du J, Tang X, Li J, Wei B, Tang C. The upregulation of endothelial nitric oxide synthase and urotensin-II is associated with pulmonary hypertension and vascular diseases in rats produced by aortocaval shunting. Heart Vessels 19: 81-88, 2004. (Pubitemid 38489035)
100. Rdzanek A, Filipiak KJ, Karpinski G, Grabowski M, Opolski G. Exercise urotensin II dynamics in myocardial infarction survivors with and without hypertension. Int J Cardiol 110: 175-178, 2006. (Pubitemid 43767107)
101. Richards M, Gary Nicholls M, Lainchbury JG, Fisher S, Yandle TG. Plasma urotensin II in heart failure. Lancet 360: 545-546, 2002.
102. Russell FD, Meyers D, Galbraith AJ, Bett N, Toth I, Kearns P, Molenaar P. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol 285: H1576-H1581, 2003. (Pubitemid 37169512)
103. Samson W, Zhang J, Avsian-Kretchmer O, Cui K, Yosten G, Klein C, Lyu RM, Wang Y, Chen X, Yang J, Price C, Hoyda T, Ferguson A, Yuan XB, Chang J, Hsueh A. Neuronostatin encoded by the somatostatin gene regulates neuronal, cardiovascular, and metabolic functions. J Biol Chem 283: 31949-31959, 2008.
104. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108: 2154-2169, 2003. (Pubitemid 37337595)
105. Segain JP, Rolli-Derkinderen M, Gervois N, Raingeard de la Bletiere D, Loirand G, Pacaud P. Urotensin II is a new chemotactic factor for UT receptor-expressing monocytes. J Immunol 179: 901-909, 2007.
106. Shenouda A, Douglas SA, Ohlstein EH, Giaid A. Localization of urotensin-II immunoreactivity in normal human kidneys and renal carcinoma. J Histochem Cytochem 50: 885-890, 2002. (Pubitemid 34774599)
107. Sheridan MA, Plisetskaya EM, Bern HA, Gorbman A. Effects of somatostatin-25 and urotensin II on lipid and carbohydrate metabolism of coho salmon, Oncorhynchus kisutch. Gen Comp Endocrinol 66: 405-414, 1987. (Pubitemid 17120612)
108. Sidharta P, van Giersbergen P, Dingemanse JJ. Pharmacokinetics and pharmacodynamics of the urotensin-II receptor antagonist palosuran in healthy male subjects. J Clin Pharmacol 49: 1168-1175, 2009.
109. Sidharta PN, Rave K, Heinemann L, Chiossi E, Krähenbühl S, Dingemanse J. Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitus. Br J Clin Pharmacol 68: 502-510, 2009.
110. Sidharta PN, Wagner FD, Bohnemeier H, Jungnik A, Halabi A, Krahenbuhl S, Chadha-Boreham H, Dingemanse J. Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin Pharmacol Ther 80: 246-256, 2006. (Pubitemid 44313907)
111. Silvestre R, Egido E, Hernandez R, Leprince J, Chatenet D, Tollemer H, Chartrel N, Vaudry H, Marco J. Urotensin-II is present in pancreatic extracts and inhibits insulin release in the perfused rat pancreas. Eur J Endocrinol 151: 803-809, 2004. (Pubitemid 40090022)
112. Silvestre RA, Rodríguez-Gallardo J, Egido EM, Marco J. Inhibition of insulin release by urotensin II-A study on the perfused rat pancreas. Horm Metab Res 33: 379-381, 2001. (Pubitemid 32625709)
113. Sondermeijer B, Kompa A, Komesaroff P, Krum H. Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension. Am J Hypertens 18: 1195-1199, 2005. (Pubitemid 41337972)
114. Song W, Abdel-Razik A, Lu W, Ao Z, Johns D, Douglas S, Balment R, Ashton N. Urotensin II and renal function in the rat. Kidney Int 69: 1360-1368, 2006.
115. Stirrat A, Gallagher M, Douglas SA, Ohlstein EH, Berry C, Kirk A, Richardson M, MacLean MR. Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol 280: H925-H928, 2001. (Pubitemid 32466939)
116. Sugo T, Mori M. Another ligand fishing for G protein-coupled receptor 14: discovery of urotensin II-related peptide in the rat brain. Peptides 29: 809-812, 2008. (Pubitemid 351522358)
117. Sugo T, Murakami Y, Shimomura Y, Harada M, Abe M, Ishibashi Y, Kitada C, Miyajima N, Suzuki N, Mori M, Fujino M. Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain. Biochem Biophys Res Commun 310: 860-868, 2003. (Pubitemid 37188701)
118. Suguro T, Watanabe T, Ban Y, Kodate S, Misaki A, Hirano T, Miyazaki A, Adachi M. Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension. Am J Hypertens 20: 211-217, 2007. (Pubitemid 46150023)
119. Suguro T, Watanabe T, Kodate S, Xu G, Hirano T, Adachi M, Miyazaki A. Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in Type 2 diabetes. Clin Sci 115: 327-334, 2008.
120. Sun HX, Du WN, Zuo J, Wu GD, Shi GB, Shen Y, Qiang BQ, Yao ZJ, Hang JM, Wang H, Huang W, Chen Z, Fang FD. The association of two single nucleotide polymorphisms in PRKCZ and UTS2 respectively with type 2 diabetes in Han people of northern China. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 24: 223-227, 2002.
121. Takahashi K, Totsune K, Murakami O, Arihara Z, Noshiro T, Hayashi Y, Shibahara S. Expression of urotensin II and its receptor in adrenal tumors and stimulation of proliferation of cultured tumor cells by urotensin II. Peptides 24: 301-306, 2003. (Pubitemid 36369351)
122. Takahashi K, Totsune K, Murakami O, Shibahara S. Expression of urotensin II and urotensin II receptor mRNAs in various human tumor cell lines and secretion of urotensin II-like immunoreactivity by SW-13 adrenocortical carcinoma cells. Peptides 22: 1175-1179, 2001. (Pubitemid 32614141)
123. Tölle M, van der Giet M. Cardiorenovascular effects of urotensin II and the relevance of the UT receptor. Peptides 29: 743-763, 2008. (Pubitemid 351522367)
124. Tooke JE, Hannemann MM. Adverse endothelial function and the insulin resistance syndrome. J Intern Med 247: 425-431, 2000. (Pubitemid 30253160)
125. Tostivint H, Joly L, Lihrmann I, Parmentier C, Lebon A, Morisson M, Calas A, Ekker M, Vaudry H. Comparative genomics provides evidence for close evolutionary relationships between the urotensin II and somatostatin gene families. Proc Natl Acad Sci USA 103: 2237-2242, 2006. (Pubitemid 43271653)
126. Tostivint H, Lihrmann I, Vaudry H. New insight into the molecular evolution of the somatostatin family. Mol Cell Endocrinol 286: 5-17, 2008.
127. Totsune K, Takahashi K, Arihara Z, Sone M, Ito S, Murakami O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci 104: 1-5, 2003. (Pubitemid 36249917)
128. Totsune K, Takahashi K, Arihara Z, Sone M, Murakami O, Ito S, Kikuya M, Ohkubo T, Hashimoto J, Imai Y. Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides 25: 1809-1814, 2004.
129. Totsune K, Takahashi K, Arihara Z, Sone M, Satoh F, Ito S, Kimura Y, Sasano H, Murakami O. Role of urotensin II in patients on dialysis. Lancet 358: 810-811, 2001.
130. Tran L, Phrommintikul A, Kemp W, Krum H, Kompa A. Systemic urotensin II infusion induces diastolic dysfunction in normal rat heart with increased collagen deposition independent of systemic blood pressure effects. Heart Lung Circ 17: S46-S47, 2008.
131. Trebicka J, Leifeld L, Hennenberg M, Biecker E, Eckhardt A, Fischer N, Pröbsting AS, Clemens C, Lammert F, Sauerbruch T, Heller J. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. Hepatology 47: 1264-1276, 2008. (Pubitemid 351547913)
132. Tsai CS, Loh SH, Liu JC, Lin JW, Chen YL, Chen CH, Cheng TH. Urotensin II-induced endothelin-1 expression and cell proliferation via epidermal growth factor receptor transactivation in rat aortic smooth muscle cells. Atherosclerosis 206: 86-94, 2009.
133. Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F, Kelly DJ, Gilbert RE, Krum H. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 93: 246-253, 2003. (Pubitemid 36993236)
134. Vale W, Brazeau P, Grant G, Nussey A, Burgus R, Rivier J, Ling N, Guillemin R. Preliminary observations on the mechanism of action of somatostatin, a hypothalamic factor inhibiting the secretion of growth hormone. C R Acad Sci Hebd Seances Acad Sci D 275: 2913-2916, 1972.
135. Wang H, Mehta JL, Chen K, Zhang X, Li D. Human urotensin II modulates collagen synthesis and the expression of MMP-1 in human endothelial cells. J Cardiovasc Pharmacol 44: 577-581, 2004. (Pubitemid 39441698)
136. Wang YX, Ding YJ, Zhu YZ, Shi Y, Yao T, Zhu YC. Role of PKC in the novel synergistic action of urotensin II and angiotensin II and in urotensin II-induced vasoconstriction. Am J Physiol Heart Circ Physiol 292: H348-H359, 2007. (Pubitemid 46105197)
137. Wang ZJ, Shi LB, Xiong ZW, Zhang LF, Meng L, Bu DF, Tang CS, Ding WH. Alteration of vascular urotensin II receptor in mice with apolipoprotein E gene knockout. Peptides 27: 858-863, 2006.
138. Watanabe T, Kanome T, Miyazaki A, Katagiri T. Human urotensin II as a link between hypertension and coronary artery disease. Hypertens Res 29: 375-387, 2006. (Pubitemid 44102804)
139. Watanabe T, Suguro T, Kanome T, Sakamoto Yi Kodate S, Hagiwara T, Hongo S, Hirano T, Adachi M, Miyazaki A. Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. Hypertension 46: 738-744, 2005. (Pubitemid 43186747)
140. Watson AMD, Lambert GW, Smith KJ, May CN. Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension 42: 373-379, 2003.
141. Wenyi Z, Suzuki S, Hirai M, Hinokio Y, Tanizawa Y, Matsutani A, Satoh J, Oka Y. Role of urotensin II gene in genetic susceptibility to Type 2 diabetes mellitus in Japanese subjects. Diabetologia 46: 972-976, 2003. (Pubitemid 36961321)
142. Wilkinson I, Affolter J, de Haas SL, Paola Pellegrini M, Boyd J, Winter M, Balment R, Webb D. High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc Res 53: 341-347, 2002. (Pubitemid 34117684)
143. Wilkinson IB, Affolter JT, de Haas SL, Paola Pellegrini M, Boyd J, Winter MJ, Balment RJ, Webb DJ. High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc Res 53: 341-347, 2002. (Pubitemid 34117684)
144. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, Kastarinen M, Poulter N, Primatesta P, Rodriguez- Artalejo F, Stegmayr B, Thamm M, Tuomilehto J, Vanuzzo D, Vescio F. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 289: 2363-2369, 2003. (Pubitemid 37430168)
145. Yoshimoto T, Matsushita M, Hirata Y. Role of urotensin II in peripheral tissue as an autocrine/paracrine growth factor. Peptides 25: 1775-1781, 2004. (Pubitemid 39346220)
146. Yu G, Yang T, Borlongan C, Stahl C, Xie X, Wang Y, Xie W, Xia K. Decreased plasma urotensin II levels inversely correlate with extent and severity of coronary artery disease. Am J Geriatr Cardiol 4: 105-110, 2007. (Pubitemid 350067421)
147. Zhang AY, Chen YF, Zhang DX, Yi FX, Qi J, Andrade-Gordon P, de Garavilla L, Li PL, Zou AP. Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am J Physiol Renal Physiol 285: F792-F798, 2003. (Pubitemid 37140263)
148. Zhang Y, Li J, Cao J, Chen J, Yang J, Zhang Z, Du J, Tang C. Effect of chronic hypoxia on contents of urotensin II and its functional receptors in rat myocardium. Heart Vessels 16: 64-68, 2002. (Pubitemid 34110716)
149. Zheng-Pei Z, Guo-Qiang LIU, Han-Zhong LI, Xin-Rong FAN, Dong-Mei LIU, An-LI T, Xin Z, Chang LIU. The effects of urotensin-II on proliferation of pheochromocytoma cells and mRNA expression of urotensin-II and its receptor in pheochromocytoma tissues. Ann NY Acad Sci 1073: 284-289, 2006.
150. Zhong P, Li Z, Wu H, Tang CS, Lu Q. Clinical study of changes of urotensin II in patients with congestive heart failure. Di Yi Jun Yi Da Xue Xue Bao 23: 121-123, 2003.
151. Zhu F, Ji L, Luo B. The role of urotensin II gene in the genetic susceptibility to type 2 diabetes in Chinese population. Zhonghua Yi Xue Za Zhi 82: 1473-1475, 2002.
152. Zhu Y, Zhu Y, Moore P. The role of urotensin II in cardiovascular and renal physiology and diseases. Br J Pharmacol 148: 884-901, 2006. (Pubitemid 44543606)
153. Zhu YZ, Wang ZJ, Zhu YC, Zhang L, Oakley RME, Chung CW, Lim KW, Lee HS, Ozoux ML, Linz W, Bohm M, Kostenis E. Urotensin II causes fatal circulatory collapse in anesthesized monkeys in vivo: a "vasoconstrictor" with a unique hemodynamic profile. Am J Physiol Heart Circ Physiol 286: H830-H836, 2004.
154. Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Pizzini P, Cutrupi S, Malatino L. Urotensin II and cardiomyopathy in end-stage renal disease. Hypertension 51: 326-333, 2008.
155. Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Pizzini P, Malatino L. Urotensin II is an inverse predictor of incident cardiovascular events in end-stage renal disease. Kidney Int 69: 1253-1258, 2006.